Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 01/07/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications

Infusion therapies for Parkinson's disease: where are we in 2025?

Infusion therapies for Parkinson's disease: where are we in 2025?

Journal: Expert opinion on drug delivery
Published: October 17, 2025

Letter to the Editor on "Cognitive and Psychiatric Adverse Effects of Foslevodopa/Foscarbidopa in Patients with Parkinson's Disease".

Letter to the Editor on "Cognitive and Psychiatric Adverse Effects of Foslevodopa/Foscarbidopa in Patients with Parkinson's Disease".

Journal: Movement disorders clinical practice
Published: October 14, 2025

Reply: "Navigating the Neuropsychiatric Risks of Foslevodopa/Foscarbidopa in Patients with Parkinson's Disease".

Reply: "Navigating the Neuropsychiatric Risks of Foslevodopa/Foscarbidopa in Patients with Parkinson's Disease".

Journal: Movement disorders clinical practice
Published: August 14, 2025

Titration Dynamics and Early Treatment Burden in Advanced Parkinson's Disease: A Multicenter Comparison of CSFLI and LCIG Infusion Therapies.

Titration Dynamics and Early Treatment Burden in Advanced Parkinson's Disease: A Multicenter Comparison of CSFLI and LCIG Infusion Therapies.

Journal: Movement disorders clinical practice
Published: July 31, 2025

Onapgo - an apomorphine subcutaneous infusion for Parkinson's disease.

Onapgo - an apomorphine subcutaneous infusion for Parkinson's disease.

Journal: The Medical letter on drugs and therapeutics
Published: July 12, 2025

Switching from Levodopa/Carbidopa Intestinal Gel to Continuous Subcutaneous Foslevodopa/Carbidopa Infusion in Advanced Parkinson's Disease: A Case Series.

Switching from Levodopa/Carbidopa Intestinal Gel to Continuous Subcutaneous Foslevodopa/Carbidopa Infusion in Advanced Parkinson's Disease: A Case Series.

Journal: Movement disorders clinical practice
Published: July 09, 2025

Parkinsonism-hyperpyrexia syndrome due to gastroparesis treated with subcutaneous foslevodopa: a case report.

Parkinsonism-hyperpyrexia syndrome due to gastroparesis treated with subcutaneous foslevodopa: a case report.

Journal: Journal of neurology
Published: June 27, 2025

Subcutaneous Foslevodopa as Rescue Therapy for Abrupt Interruption of Oral Dopaminergic Treatment in Parkinson's Disease.

Subcutaneous Foslevodopa as Rescue Therapy for Abrupt Interruption of Oral Dopaminergic Treatment in Parkinson's Disease.

Journal: Movement disorders clinical practice
Published: June 13, 2025

Clinical Impact of Switching from Subcutaneous Apomorphine to Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease: A Real-World Observational Study (FOSAPO).

Clinical Impact of Switching from Subcutaneous Apomorphine to Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease: A Real-World Observational Study (FOSAPO).

Journal: Movement disorders clinical practice
Published: May 30, 2025

Switching Gears: From Intrajejunal Levodopa to Subcutaneous Foslevodopa.

Switching Gears: From Intrajejunal Levodopa to Subcutaneous Foslevodopa.

Journal: Movement disorders clinical practice
Published: May 21, 2025

Continuous subcutaneous infusion therapies in Parkinson's disease: evidence of efficacy and safety.

Continuous subcutaneous infusion therapies in Parkinson's disease: evidence of efficacy and safety.

Journal: Parkinsonism & related disorders
Published: May 12, 2025

Subcutaneous foslevodopa/foscarbidopa initiation in a Parkinson's day-clinic - a suitable setting to ensure treatment efficacy, tolerability and psychosocial adaption.

Subcutaneous foslevodopa/foscarbidopa initiation in a Parkinson's day-clinic - a suitable setting to ensure treatment efficacy, tolerability and psychosocial adaption.

Journal: Frontiers in aging neuroscience
Published: April 28, 2025
Showing 1-12 of 29

Last Updated: 01/07/2026